uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $58.3333.

Several analysts recently commented on the company. Barclays began coverage on uniQure in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price objective on the stock. Royal Bank Of Canada lowered their price target on uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Chardan Capital reiterated a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th. Finally, The Goldman Sachs Group lowered their target price on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th.

Insider Activity at uniQure

In other news, Director Robert Gut sold 25,613 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director owned 32,342 shares of the company’s stock, valued at $796,260.04. This represents a 44.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the sale, the director owned 20,439 shares in the company, valued at approximately $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.79% of the stock is owned by corporate insiders.

Institutional Trading of uniQure

A number of institutional investors have recently modified their holdings of the company. Woodline Partners LP grew its holdings in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in uniQure during the 2nd quarter worth approximately $117,000. Y Intercept Hong Kong Ltd bought a new position in shares of uniQure during the 2nd quarter worth approximately $872,000. Teacher Retirement System of Texas bought a new position in shares of uniQure during the 2nd quarter worth approximately $151,000. Finally, Jennison Associates LLC acquired a new stake in shares of uniQure in the second quarter valued at approximately $1,952,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Stock Down 7.2%

Shares of NASDAQ:QURE opened at $22.37 on Friday. The company has a 50 day moving average price of $23.39 and a two-hundred day moving average price of $28.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The company has a market capitalization of $1.39 billion, a PE ratio of -5.10 and a beta of 0.66. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. Analysts forecast that uniQure will post -3.75 earnings per share for the current year.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Profile/coverage unrelated to the litigation but included in the feed (may be ignored by most investors). Sarah Tabrizi
• Negative Sentiment: Kessler Topaz has filed a securities‑fraud class action against uniQure on behalf of investors who bought shares between Sept. 24 and Oct. 31, 2025. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) – Contact Kessler Topaz Meltzer & Check, LLP
• Negative Sentiment: Multiple firms are soliciting lead‑plaintiff applicants and reminding investors of an April 13, 2026 deadline to join cases tied to the Sept.‑Oct. 2025 class period — signaling coordination of litigation activity. Example reminder from ClaimsFiler. uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. – QURE
• Negative Sentiment: Holzer & Holzer and other firms allege uniQure made false/misleading statements and failed to disclose material issues — specifically that the pivotal study design and comparisons to ENROLL‑HD were not fully FDA‑approved and a BLA delay was likely. INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of uniQure N.V. (QURE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
• Negative Sentiment: Bloomberg Law and others report investor suits specifically over the delayed Huntington’s drug application — media coverage increases visibility and may accelerate selling pressure. UniQure Investor Sues Over Delayed Huntington’s Drug Application
• Negative Sentiment: Multiple additional plaintiff firms (Rosen, Faruqi, Bernstein Liebhard, Berger Montague, Schall, etc.) have announced investigations or filings — the sheer number of firms increases probability of consolidated litigation and potential legal exposure. Example: Faruqi deadline notice. QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.